215 related articles for article (PubMed ID: 34994207)
1. Clinical Significance of Frailty on Treatment Outcome in Nongeriatric Patients With Head and Neck Cancer and Esophageal Cancer Undergoing Curative-Intent Concurrent Chemoradiotherapy.
Chou WC; Lai CC; Hung CY; Hsueh SW; Yeh KY; Lu CH; Tsang NM; Chang PH; Ho YW; Chen SY; Lin YC; Hung YS
Cancer Control; 2022; 29():10732748211045276. PubMed ID: 34994207
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of Vulnerability Assessment in Patients with Primary Head and Neck Cancer Undergoing Definitive Concurrent Chemoradiation Therapy.
Chou WC; Chang PH; Chen PT; Wang HM; Yeh KY; Lu CH; Hung YS; Tung-Chieh Chang J; Tsang NM; Ho YW; Chen SY; Lee SH; Hung CY; Wang LJ; Liao KC; Lin CH; Tang WR; Lin YC
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):602-611. PubMed ID: 31987971
[TBL] [Abstract][Full Text] [Related]
3. Impact of Frailty on Treatment Outcome in Patients With Locally Advanced Esophageal Cancer Undergoing Concurrent Chemoradiotherapy.
Huang YH; Hung YS; Lai CC; Ho MM; Yeh KY; Yang C; Lu CH; Tseng CK; Tsang NM; Hung CY; Hsueh SW; Chang PH; Ho YW; Lin YC; Chou WC
Anticancer Res; 2021 Oct; 41(10):5213-5222. PubMed ID: 34593474
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer.
Chitapanarux I; Tharavichitkul E; Kamnerdsupaphon P; Pukanhapan N; Vongtama R
J Radiat Res; 2013 Nov; 54(6):1110-7. PubMed ID: 23740894
[TBL] [Abstract][Full Text] [Related]
5. Frailty is an independent factor for health-related quality of life in patients with head and neck cancer receiving definitive concurrent chemoradiotherapy.
Lu CH; Hung CY; Hsueh SW; Yeh KY; Hung YS; Chou WC
Support Care Cancer; 2024 Jan; 32(2):106. PubMed ID: 38221588
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the MNA-SF, MUST, and NRS-2002 nutritional tools in predicting treatment incompletion of concurrent chemoradiotherapy in patients with head and neck cancer.
Hsueh SW; Lai CC; Hung CY; Lin YC; Lu CH; Yeh KY; Tsang NM; Hung YS; Chang PH; Chou WC
Support Care Cancer; 2021 Sep; 29(9):5455-5462. PubMed ID: 33704566
[TBL] [Abstract][Full Text] [Related]
7. Frailty assessment by two screening instruments in non-elderly patients with head and neck cancer.
Yu SM; Hsu CC; Hsueh SW; Hung CY; Lu CH; Yeh KY; Wang HM; Lin SY; Hung YS; Chou WC
Oral Oncol; 2023 Dec; 147():106621. PubMed ID: 37931492
[TBL] [Abstract][Full Text] [Related]
8. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma.
Zhou XL; Yu CH; Wang WW; Ji FZ; Xiong YZ; Zhu WG; Tong YS
Radiat Oncol; 2021 May; 16(1):94. PubMed ID: 34039375
[TBL] [Abstract][Full Text] [Related]
9. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study.
Lyu J; Li T; Wang Q; Li F; Diao P; Liu L; Li C; Lang J
Radiat Oncol; 2018 Nov; 13(1):233. PubMed ID: 30477531
[TBL] [Abstract][Full Text] [Related]
11. The Geriatric Nutritional Risk Index as a prognostic factor in older adult patients with locally advanced head and neck cancer receiving definitive chemoradiotherapy with tri-weekly cisplatin.
Fujiwara Y; Sato Y; Hayashi N; Fukuda N; Wang X; Nakano K; Ohmoto A; Urasaki T; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takahashi S
J Geriatr Oncol; 2023 Jun; 14(5):101523. PubMed ID: 37229881
[TBL] [Abstract][Full Text] [Related]
12. Emergency department visits and unplanned hospitalizations in the treatment period for head and neck cancer patients treated with curative intent: A population-based analysis.
Eskander A; Krzyzanowska MK; Fischer HD; Liu N; Austin PC; Irish JC; Enepekides DJ; Lee J; Gutierrez E; Lockhart E; Raphael M; Singh S
Oral Oncol; 2018 Aug; 83():107-114. PubMed ID: 30098764
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
Yen YC; Chang JH; Lin WC; Chiou JF; Chang YC; Chang CL; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
Cancer; 2017 Jun; 123(11):2043-2053. PubMed ID: 28152166
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Induction Chemotherapy for Head and Neck Cancer Patients: A Combined Study of Two National Cohorts in Taiwan.
Chen JH; Yen YC; Liu SH; Yuan SP; Wu LL; Lee FP; Lin KC; Lai MT; Wu CC; Chen TM; Chang CL; Chow JM; Ding YF; Lin MC; Wu SY
Medicine (Baltimore); 2016 Feb; 95(7):e2845. PubMed ID: 26886647
[TBL] [Abstract][Full Text] [Related]
15. Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
Voncken FEM; van der Kaaij RT; Sikorska K; van Werkhoven E; van Dieren JM; Grootscholten C; Snaebjornsson P; van Sandick JW; Aleman BMP
Am J Clin Oncol; 2018 Sep; 41(9):919-926. PubMed ID: 28763327
[TBL] [Abstract][Full Text] [Related]
16. Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.
Lin WC; Ding YF; Hsu HL; Chang JH; Yuan KS; Wu ATH; Chow JM; Chang CL; Chen SU; Wu SY
Cancer; 2017 Oct; 123(20):3904-3915. PubMed ID: 28608916
[TBL] [Abstract][Full Text] [Related]
17. Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy.
Pao TH; Chang WL; Chiang NJ; Chang JS; Lin CY; Lai WW; Tseng YL; Yen YT; Chung TJ; Lin FC
Radiat Oncol; 2020 Sep; 15(1):221. PubMed ID: 32962730
[TBL] [Abstract][Full Text] [Related]
18. Potential Utility of the Mallampati Score for Prediction of Treatment Compliance and Safety Profiles of Patients With Head and Neck Cancer Undergoing Definitive Concurrent Chemoradiotherapy.
Su PH; Hsu CC; Hsueh SW; Hung CY; Yeh KY; Wang HM; Lu CH; Lin YC; Chang JT; Chou WC
Anticancer Res; 2022 Nov; 42(11):5609-5618. PubMed ID: 36288852
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
[TBL] [Abstract][Full Text] [Related]
20. Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis.
Zhang L; Jiang N; Shi Y; Li S; Wang P; Zhao Y
Sci Rep; 2015 Jun; 5():10798. PubMed ID: 26041604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
